Edition:
United States

Miragen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

8.01USD
11 Dec 2017
Change (% chg)

$0.01 (+0.12%)
Prev Close
$8.00
Open
$8.01
Day's High
$8.01
Day's Low
$8.01
Volume
101
Avg. Vol
24,909
52-wk High
$17.83
52-wk Low
$4.65

Chart for

About

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product... (more)

Overall

Beta: 1.86
Market Cap(Mil.): $178.48
Shares Outstanding(Mil.): 22.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Miragen Therapeutics reports third quarter financial results

* Miragen Therapeutics reports third quarter 2017 financial results and provides corporate update

Nov 08 2017

BRIEF-Miragen Therapeutics presents new data suggesting positive impact from systemically administered MRG-106

* Miragen Therapeutics presents new clinical data suggesting positive impact from systemically administered MRG-106 on mycosis fungoides form of cutaneous T-cell lymphoma at EORTC global task force meeting

Oct 13 2017

BRIEF-Miragen Therapeutics presents new MRG-201 preclinical data

* Miragen Therapeutics presents new MRG-201 preclinical data for Inhaled Microrna-29 Mimic Targeting Pulmonary Fibrosis Source text for Eikon: Further company coverage:

Sep 11 2017

BRIEF-Miragen Therapeutics Q2 loss per share $0.34

* Miragen Therapeutics reports second quarter 2017 financial results and provides corporate update

Aug 11 2017

Earnings vs. Estimates